Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept : Results from the APPRAISE study. / D'Agostino, Maria-Antonietta; Boers, Maarten; Wakefield, Richard J; Hammer, Hilde Berner; Vittecoq, Olivier; Filippou, Georgios; Balint, Peter; Möller, Ingrid; Iagnocco, Annamaria; Naredo, Esperanza; Østergaard, Mikkel; Gaillez, Corine; Le Bars, Manuela.

I: RMD Open: Rheumatic & Musculoskeletal Diseases, Bind 2, Nr. 1, e000237, 2016.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

D'Agostino, M-A, Boers, M, Wakefield, RJ, Hammer, HB, Vittecoq, O, Filippou, G, Balint, P, Möller, I, Iagnocco, A, Naredo, E, Østergaard, M, Gaillez, C & Le Bars, M 2016, 'Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study', RMD Open: Rheumatic & Musculoskeletal Diseases, bind 2, nr. 1, e000237. https://doi.org/10.1136/rmdopen-2015-000237

APA

D'Agostino, M-A., Boers, M., Wakefield, R. J., Hammer, H. B., Vittecoq, O., Filippou, G., Balint, P., Möller, I., Iagnocco, A., Naredo, E., Østergaard, M., Gaillez, C., & Le Bars, M. (2016). Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study. RMD Open: Rheumatic & Musculoskeletal Diseases, 2(1), [e000237]. https://doi.org/10.1136/rmdopen-2015-000237

Vancouver

D'Agostino M-A, Boers M, Wakefield RJ, Hammer HB, Vittecoq O, Filippou G o.a. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study. RMD Open: Rheumatic & Musculoskeletal Diseases. 2016;2(1). e000237. https://doi.org/10.1136/rmdopen-2015-000237

Author

D'Agostino, Maria-Antonietta ; Boers, Maarten ; Wakefield, Richard J ; Hammer, Hilde Berner ; Vittecoq, Olivier ; Filippou, Georgios ; Balint, Peter ; Möller, Ingrid ; Iagnocco, Annamaria ; Naredo, Esperanza ; Østergaard, Mikkel ; Gaillez, Corine ; Le Bars, Manuela. / Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept : Results from the APPRAISE study. I: RMD Open: Rheumatic & Musculoskeletal Diseases. 2016 ; Bind 2, Nr. 1.

Bibtex

@article{fdbad7effd1a4f80bfaa544d04e24e1c,
title = "Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study",
abstract = "Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.",
author = "Maria-Antonietta D'Agostino and Maarten Boers and Wakefield, {Richard J} and Hammer, {Hilde Berner} and Olivier Vittecoq and Georgios Filippou and Peter Balint and Ingrid M{\"o}ller and Annamaria Iagnocco and Esperanza Naredo and Mikkel {\O}stergaard and Corine Gaillez and {Le Bars}, Manuela",
year = "2016",
doi = "10.1136/rmdopen-2015-000237",
language = "English",
volume = "2",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept

T2 - Results from the APPRAISE study

AU - D'Agostino, Maria-Antonietta

AU - Boers, Maarten

AU - Wakefield, Richard J

AU - Hammer, Hilde Berner

AU - Vittecoq, Olivier

AU - Filippou, Georgios

AU - Balint, Peter

AU - Möller, Ingrid

AU - Iagnocco, Annamaria

AU - Naredo, Esperanza

AU - Østergaard, Mikkel

AU - Gaillez, Corine

AU - Le Bars, Manuela

PY - 2016

Y1 - 2016

N2 - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

AB - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

U2 - 10.1136/rmdopen-2015-000237

DO - 10.1136/rmdopen-2015-000237

M3 - Journal article

C2 - 27175297

AN - SCOPUS:84987962115

VL - 2

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - e000237

ER -

ID: 179087348